Drug intelligence / Profile preview

DPMAE

Development stage: Preclinical
Lead developer: Ankang Traditional Chinese Medicine Hospital
Administration: Oral

Overview

DPMAE is a substance under investigation for its role in treating acute-on-chronic liver failure. It is administered orally in combination with "Bugan Shengjiang Tang". This combined treatment is being studied for its mechanism in regulating liver cell regeneration through the "CSS/MD" signal pathway. The exact chemical nature or specific class of DPMAE is not detailed in the provided context.

Beyond the preview

Go deeper on DPMAE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DPMAE.

Explore the full profile